| 貨號(hào) | 規(guī)格 | 價(jià)格 | 上海 | 北京 | 武漢 | 南京 | 購(gòu)買(mǎi)數(shù)量 |
|---|---|---|---|---|---|---|---|
S87309-1mg |
99.4% | ￥80.00 | 10 | - | - | - |
|
S87309-2mg |
99.4% | ￥110.00 | 10 | - | - | - |
|
S87309-5mg |
99.4% | ￥170.00 | 10 | - | - | - |
|
S87309-10mg |
99.4% | ￥230.00 | 7 | - | - | - |
|
S87309-25mg |
≥99% | ￥440.00 | 貨期：2-3天 | - | - | - |
|
S87309-50mg |
≥99% | ￥650.00 | 貨期：2-3天 | - | - | - |
|
S87309-100mg |
≥99% | ￥950.00 | 貨期：2-3天 | - | - | - |
|
Elafibranor (GFT505) 是PPAR-alpha和PPAR-δ的激動(dòng)劑，改善胰島素敏感度、有益于葡萄糖穩(wěn)態(tài)、脂質(zhì)代謝并減少炎癥
| 產(chǎn)品描述： | Elafibranor (GFT505) 是PPAR-alpha和PPAR-δ的激動(dòng)劑，改善胰島素敏感度、有益于葡萄糖穩(wěn)態(tài)、脂質(zhì)代謝并減少炎癥 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點(diǎn)： | PPARα; PPARδ ;PPAR | ||||||||||||||||||||
| 體外研究： | GFT505 is a novel PPAR modulator that shows a preferential activity on PPAR-α and concomitant activity on PPAR-δ | ||||||||||||||||||||
| 體內(nèi)研究： | Elafibranor (GFT505) is a dual PPARα/δ agonist that has demonstrated efficacy in disease models of nonalcoholic fatty liver disease (NAFLD)/NASH and liver fibrosis. In the rat, GFT505 concentrated in the liver with limited extrahepatic exposure and underwent extensive enterohepatic cycling. Elafibranor confers liver protection by acting on several pathways involved in NASH pathogenesis, reducing steatosis, inflammation, and fibrosis. GFT505 improved liver dysfunction markers, decreased hepatic lipid accumulation, and inhibited proinflammatory (interleukin-1 beta, tumor necrosis factor alpha, and F4/80) and profibrotic (transforming growth factor beta, tissue inhibitor of metalloproteinase 2, collagen type I, alpha 1, and collagen type I, alpha 2) gene expression | ||||||||||||||||||||
| 細(xì)胞實(shí)驗(yàn)： | Cell lines: hSKP-HPCs Concentrations: 30 μM Incubation Time: 24 h Method: Cells were treated with indicated concentration of drug for 24 h. | ||||||||||||||||||||
| 動(dòng)物實(shí)驗(yàn)： | Animal Models: hApoE2 KI and hApoE2 KI/PPAR-α KO mice Dosages: 30 mg/kg Administration: oral gavage | ||||||||||||||||||||
| 參考文獻(xiàn)： | 1. Ratziu V, et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016, 150(5):1147-1159.e5. 2. Staels B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013, 58(6):1941-52. 3. Boeckmans J, et al. Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH. Pharmacol Res. 2019 Jun;144:377-389. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO、Ethanol | ||||||||||||||||||||
| 保存條件： | -20℃ | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
滬公網(wǎng)安備 31011702002021號(hào)
危險(xiǎn)品化學(xué)品經(jīng)營(yíng)許可證（不帶存儲(chǔ)）
營(yíng)業(yè)執(zhí)照(三證合一)
掃一掃關(guān)注上海源葉微信公眾號(hào)
北京